Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Terminated 1Suspended 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Melanoma 1Locally Advanced Rectal Adenocarcinoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 1282Specimen Handling 927Carboplatin 836Magnetic Resonance Spectroscopy 834Cyclophosphamide 807Cisplatin 735Nivolumab 680Paclitaxel 635Radiotherapy 617Gemcitabine 580Biopsy 559Bevacizumab 485Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 361Fluorouracil 357atezolizumab 350durvalumab 340Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 319Blood Specimen Collection 317Standard of Care 311Pemetrexed 307Ipilimumab 303Radiation 287

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
sotigalimab × 1 year × Clear all
NCT05419479 2026-06-04

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended
46 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04130854 2026-05-06

INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer

University of Texas Southwestern Medical Center

Phase 2 Completed
58 enrolled
Gastrointestinal

Locally Advanced Rectal Adenocarcinoma

NCT02600949 2026-04-24

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
300 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02706353 2025-11-21

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
34 enrolled 18 charts
Dermatologic

Melanoma

NCT04495257 2025-10-30

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

Yale University

Phase 1 Active not recruiting
26 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡